Role of microRNA-373 in tumor

doi:10.3760/cma.j.issn.1673-422X.2018.06.008

Abstract

Abstract: MicroRNAs are non-coding small RNAs that participate in the regulation of post transcriptional gene expression. MicroRNAs play the roles of inhibiting cancer or promoting cancer in different tumors. MicroRNA-373 is one of the members of the microRNA-520/373 family, which is involved in cancer anoxic response and DNA damage repair. MicroRNA-373 is abnormal expressed in breast cancer, glioma, lung cancer, prostate cancer and other tumors, which may play an important role in tumor development process, especially in tumor invasion and migration.

Key words: Neoplasms, MicroRNAs, Neoplasms metastasis, Gene expression regulation

Shen Kai, Shao Fang, Feng Tongbao, Qi Chunjian. Role of microRNA-373 in tumor[J]. Journal of International Oncology, 2018, 45(6): 355-357.

References

［1］ Wei F, Cao C, Xu X, et al. Diverse functions of miR-373 in cancer［J］. J Transl Med, 2015, 13: 162. DOI: 10.1186/s12967-015-0523-z. ［2］ Zhang Y, Yang J, Cui X, et al. A novel epigenetic CREBmiR-373 axis mediates ZIP4induced pancreatic cancer growth［J］. EMBO Mol Med, 2013, 5(9): 1322-1334. DOI: 10.1002/emmm.201302507. ［3］ Meng X, Müller V, MildeLangosch K, et al. Diagnostic and prognostic relevance of circulating exosomal miR373, miR200a, miR200b and miR-200c in patients with epithelial ovarian cancer［J］. Oncotarget, 2016, 7(13): 16923-16935. DOI: 10.18632/oncotarget.7850. ［4］ Chen D, Dang BL, Huang JZ, et al. MiR-373 drives the epithelial to mesenchymal transition and metastasis via the miR373TXNIPHIF1αTWIST signaling axis in breast cancer［J］. Oncotarget, 2015, 6(32): 3270132712. DOI: 10.18632/oncotarget.4702. ［5］ Ding W, Fan XL, Xu X, et al. Epigenetic silencing of ITGA2 by miR-373 promotes cell migration in breast cancer［J］. PLoS One, 2015, 10(8): e0135128. DOI: 10.1371/journal.pone.0135128. ［6］ O′Day E, Lal A. MicroRnas and their target gene networks in breast cancer［J］. Breast Cancer Res, 2010, 12(2): 201. DOI: 10.1186/bcr2484. ［7］ Keklikoglou I, Koerner C, Schmidt C, et al. MicroRNA520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGFβ signaling pathways［J］. Oncogene, 2012, 31(37): 41504163. DOI: 10.1038/onc.2011.571. ［8］ Jing SY, Jing SQ, Liu LL, et al. Downexpression of miR373 predicts poor prognosis of glioma and could be a potential therapeutic target［J］. Eur Rev Med Pharmacol Sci, 2017, 21(10): 2421-2425. ［9］ Wei F, Wang Q, Su Q, et al. miR373 inhibits glioma cell U251 migration and invasion by downregulating CD44 and TGFBR2［J］. Cell Mol Neurobiol, 2016, 36(8): 1389-1397. DOI: 10.1007/s10571-016-0338-3. ［10］ Lu S, Zhu Q, Zhang Y, et al. Dualfunctions of miR373 and miR520c by differently regulating the activities of MMP2 and MMP9［J］. J Cell Physiol, 2015, 230(8): 1862-1870. DOI: 10.1002/jcp.24914. ［11］ Seol HS, Akiyama Y, Shimada S, et al. Epigenetic silencing of microRNA373 to epithelialmesenchymal transition in nonsmall cell lung cancer through IRAK2 and LAMP1 axes ［J］. Cancer Lett, 2014, 353(2): 232-241. DOI: 10.1016/j.canlet.2014.07.019. ［12］ Wu W, He X, Kong J, et al. Mir373 affects human lung cancer cells′ growth and its Ecadherin expression［J］. Oncol Res, 2012, 20(4): 163-170. ［13］ Adi Harel S, Bossel BenMoshe N, Aylon Y, et al. Reactivation of epigenetically silenced miR512 and miR373 sensitizes lung cancer cells to cisplatin and restricts tumor growth［J］. Cell Death Differ, 2015, 22(8): 1328-1340. DOI: 10.1038/cdd.2014.221. ［14］ Wang L, Qu J, Zhou L, et al. MicroRNA-373 inhibits cell proliferation and invasion via targeting BRF2 in human nonsmall cell lung cancer A549 cell line［J］. Cancer Res Treat, 2017, In press. DOI: 10.4143/crt.2017.302. ［15］ Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer［J］. Am J Transl Res, 2010, 3(1): 1-7. ［16］ Yang K, Handorean AM, Iczkowski KA. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro［J］. Int J Clin Exp Pathol, 2009, 2(4): 361-369. ［17］ Walter BA, Valera VA, Pinto PA, et al. Comprehensive microRNA profiling of prostate cancer［J］. J Cancer, 2013, 4(5): 350-357. DOI: 10.7150/jca.6394. ［18］ Qiu X, Zhu J, Sun Y, et al. TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR3733p expression to alter TGFβR2/p Smad3 signals［J］. Oncotarget, 2015, 6(17): 15397-15409. DOI: 10.18632/oncotarget.3778. ［19］ Hua Y, Chen H, Wang L, et al. Low serum miR373 predicts poor prognosis in patients with pancreatic cancer［J］. Cancer Biomark, 2017, 20(1): 95-100. DOI: 10.3233/CBM-170231. ［20］ Nakata K, Ohuchida K, Mizumoto K, et al. Micro RNA373 is downregulated in pancreatic cancer and inhibits cancer cell invasion［J］. Ann Surg Oncol, 2014, 21 Suppl 4: S564-574. DOI: 10.1245/s10434-014-3676-8. ［21］ Chen YJ, Luo J, Yang GY, et al. Mutual regulation between microRNA-373 and methylCpGbinding domain protein 2 in hilar cholangiocarcinoma ［J］. World J Gastroenterol, 2012, 18(29): 3849-3861. DOI: 10.3748/wjg.v18.i29.3849. ［22］ Chen Y, Gao W, Luo J, et al. MethylCpG binding protein MBD2 is implicated in methylationmediated suppression of miR-373 in hilar cholangiocarcinoma［J］. Oncol Rep, 2011, 25(2): 443-451. DOI: 10.3892/or.2010.1089.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.